Stacy S. Shord

United States Food and Drug Administration

Also affiliated with Center for Drug Evaluation and Research

Pharmacology, Toxicology and PharmaceuticsMedicineMathematicsImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 8 papers. Top paper: “FDA Approval Summary: Dabrafenib in Combination with Trametinib for BRAFV600E Mutation–Positive Low-Grade Glioma”.

FDA Approval Summary: Dabrafenib in Combination with Trametinib for BRAFV600E Mutation–Positive Low-Grade Glioma

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1503

N/A

1.8DataRank · unranked

71 citations

Jeannette Nashed, Diana Bradford, Yi Ren, Sachia G. Khasar, Claudia P. Miller +15 more

FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome

The Oncologist(2018)10.1634/theoncologist.2018-0028

N/A

1.0DataRank · unranked

896 citations

Liang Li, Weishi Yuan, Stacy S. Shord, Lei Nie, Bahru A. Habtemariam +4 more

FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-3439

N/A

0.470DataRank · unranked

22 citations

Diana Bradford, Somak Chatterjee, Xiaoxue Li, Stephanie Aungst, Amy M. Skinner +22 more

FDA–AACR Strategies for Optimizing Dosages for Oncology Drug Products: Early-Phase Trials Using Innovative Trial Designs and Biomarkers

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-1918

N/A

0.241DataRank · unranked

4 citations

Gabriela Patilea-Vrana, Anthony Sireci, Alexia Iasonos, Brad A. Davidson, Jiang Liu +4 more

Perspectives on Drug Development for the Treatment of Chronic Myeloid Leukemia in Pregnant Patients and Patients Who Are Breastfeeding

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0826

N/A

0.241DataRank · unranked

4 citations

Elisabetta Abruzzese, Elyce Cardonick, Sonia Hernández–Dı́az, Jamie Gutierrez, Mary S. Sardegna +10 more

FDA Approval Summary: Datopotamab Deruxtecan-dlnk for Treatment of Patients with Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-1388

N/A

0DataRank · unranked

13 citations

Mirat Shah, Lijun Zhang, Joyce Cheng, Mary Kate Bonner, Melissa A. Pegues +22 more

Dosage Optimization of Pediatric Oncology Products: Our Patients Deserve Better

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-4325

N/A

0DataRank · unranked

1 citations

Nicole Drezner, Stacy S. Shord, Mirat Shah, Marc R. Theoret, Martha Donoghue +1 more

FDA–AACR Strategies for Optimizing Dosages for Oncology Drug Products: Selecting Optimized Dosages for Registrational Trials

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-0098

N/A

0DataRank · unranked

1 citations

Cong Chen, Jin Y. Jin, Scott Van Wart, Sarah K. Martin, Brad A. Davidson +4 more